{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:19:10Z","timestamp":1790720350732,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2015,3,26]],"date-time":"2015-03-26T00:00:00Z","timestamp":1427328000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1007\/s00259-015-3041-6","type":"journal-article","created":{"date-parts":[[2015,3,25]],"date-time":"2015-03-25T09:47:05Z","timestamp":1427276825000},"page":"1238-1246","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":87,"title":["Specific efficacy of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced neuroendocrine tumours of the small intestine"],"prefix":"10.1007","volume":"42","author":[{"given":"Amir","family":"Sabet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Dautzenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torjan","family":"Haslerud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Aouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Sabet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-J\u00fcrgen","family":"Biersack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer","family":"Ezziddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,3,26]]},"reference":[{"key":"3041_CR1","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000335629","volume":"95","author":"UF Pape","year":"2012","unstructured":"Pape UF, Perren A, Niederle B, Gross D, Gress T, Costa F, et al. ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology 2012;95:135\u201356.","journal-title":"Neuroendocrinology"},{"key":"3041_CR2","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1677\/ERC-09-0042","volume":"16","author":"A Ahmed","year":"2009","unstructured":"Ahmed A, Turner G, King B, Jones L, Culliford D, McCance D, et al. Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. Endocr Relat Cancer 2009;16:885\u201394.","journal-title":"Endocr Relat Cancer"},{"key":"3041_CR3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000111034","volume":"87","author":"B Eriksson","year":"2008","unstructured":"Eriksson B, Kl\u00f6ppel G, Krenning E, Ahlman H, Pl\u00f6ckinger U, Wiedenmann B, et al. Consensus guidelines for the management of patients with digestive neuroendocrine tumors\u2013well-differentiated jejunal-ileal tumor\/carcinoma. Neuroendocrinology 2008;87:8\u201319.","journal-title":"Neuroendocrinology"},{"key":"3041_CR4","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000335597","volume":"95","author":"M Pavel","year":"2012","unstructured":"Pavel M, Baudin E, Couvelard A, Krenning E, \u00d6berg K, Steinm\u00fcller T, et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2012;95:157\u201376.","journal-title":"Neuroendocrinology"},{"key":"3041_CR5","first-page":"343","volume":"14","author":"LK Kvols","year":"1987","unstructured":"Kvols LK, Buck M. Chemotherapy of endocrine malignancies: a review. Semin Oncol 1987;14:343\u201353.","journal-title":"Semin Oncol"},{"key":"3041_CR6","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1200\/JCO.2005.03.6046","volume":"24","author":"MH Kulke","year":"2006","unstructured":"Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006;24:401\u20136.","journal-title":"J Clin Oncol"},{"key":"3041_CR7","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1200\/JCO.2008.16.7858","volume":"26","author":"JC Yao","year":"2008","unstructured":"Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008;26:4311\u20138.","journal-title":"J Clin Oncol"},{"key":"3041_CR8","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/sj.bjc.6603419","volume":"95","author":"I Duran","year":"2006","unstructured":"Duran I, Kortmansky J, Singh D, Hirte H, Kocha W, Goss G, et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 2006;95:1148\u201354.","journal-title":"Br J Cancer"},{"key":"3041_CR9","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1053\/j.semnuclmed.2009.11.004","volume":"40","author":"F Gr\u00fcnwald","year":"2010","unstructured":"Gr\u00fcnwald F, Ezziddin S. 131I-metaiodobenzylguanidine therapy of neuroblastoma and other neuroendocrine tumors. Semin Nucl Med 2010;40:153\u201363.","journal-title":"Semin Nucl Med"},{"key":"3041_CR10","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1200\/JCO.2008.21.3496","volume":"27","author":"S Gonias","year":"2009","unstructured":"Gonias S, Goldsby R, Matthay KK, Hawkins R, Price D, Huberty J, et al. Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol 2009;27:4162\u20138.","journal-title":"J Clin Oncol"},{"key":"3041_CR11","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2967\/jnumed.112.119313","volume":"54","author":"S Ezziddin","year":"2013","unstructured":"Ezziddin S, Sabet A, Logvinski T, Alkawaldeh K, Yong-Hing CJ, Ahmadzadehfar H, et al. Long-term outcome and toxicity after dose-intensified treatment with 131I-MIBG for advanced metastatic carcinoid tumors. J Nucl Med 2013;54:2032\u20138.","journal-title":"J Nucl Med"},{"key":"3041_CR12","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1053\/j.semnuclmed.2009.10.004","volume":"40","author":"DJ Kwekkeboom","year":"2010","unstructured":"Kwekkeboom DJ, de Herder WW, van Eijck CH, Kam BL, van Essen M, Teunissen JJ, et al. Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 2010;40:78\u201388.","journal-title":"Semin Nucl Med"},{"key":"3041_CR13","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","volume":"26","author":"DJ Kwekkeboom","year":"2008","unstructured":"Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008;26:2124\u201330.","journal-title":"J Clin Oncol"},{"key":"3041_CR14","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1200\/JCO.2010.33.7873","volume":"29","author":"A Imhof","year":"2011","unstructured":"Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol 2011;29:2416\u201323.","journal-title":"J Clin Oncol"},{"key":"3041_CR15","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s00259-013-2677-3","volume":"41","author":"S Ezziddin","year":"2014","unstructured":"Ezziddin S, Khalaf F, Vanezi M, Haslerud T, Mayer K, Al Zreiqat A, et al. Outcome of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced grade 1\/2 pancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2014;41:925\u201333.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3041_CR16","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00259-013-2547-z","volume":"41","author":"A Sabet","year":"2014","unstructured":"Sabet A, Haslerud T, Pape UF, Ahmadzadehfar H, Gr\u00fcnwald F, Guhlke S, et al. Outcome and toxicity of salvage therapy with 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2014;41:205\u201310.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3041_CR17","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.2967\/jnumed.111.090373","volume":"52","author":"S Ezziddin","year":"2011","unstructured":"Ezziddin S, Sabet A, Heinemann F, Yong-Hing CJ, Ahmadzadehfar H, Guhlke S, et al. Response and long-term control of bone metastases after peptide receptor radionuclide therapy with (177)Lu-octreotate. J Nucl Med 2011;52:1197\u2013203.","journal-title":"J Nucl Med"},{"key":"3041_CR18","first-page":"437","volume":"3","author":"A Sabet","year":"2013","unstructured":"Sabet A, Khalaf F, Haslerud T, Al-Zreiqat A, Simon B, P\u00f6ppel TD, et al. Bone metastases in GEP-NET: response and long-term outcome after PRRT from a follow-up analysis. Am J Nucl Med Mol Imaging 2013;3:437\u201345.","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"3041_CR19","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1200\/JCO.2009.22.8585","volume":"28","author":"DL Bushnell Jr","year":"2010","unstructured":"Bushnell Jr DL, O\u2019Dorisio TM, O\u2019Dorisio MS, Menda Y, Hicks RJ, Van Cutsem E, et al. 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol 2010;28:1652\u20139.","journal-title":"J Clin Oncol"},{"key":"3041_CR20","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1007\/s00259-014-2735-5","volume":"41","author":"G Paganelli","year":"2014","unstructured":"Paganelli G, Sansovini M, Ambrosetti A, Severi S, Monti M, Scarpi E, et al. 177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study. Eur J Nucl Med Mol Imaging 2014;41:1845\u201351.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3041_CR21","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00428-007-0452-1","volume":"451","author":"G Rindi","year":"2007","unstructured":"Rindi G, Kl\u00f6ppel G, Couvelard A, Komminoth P, K\u00f6rner M, Lopes JM, et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2007;451:757\u201362.","journal-title":"Virchows Arch"},{"key":"3041_CR22","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1177\/030089161009600532","volume":"96","author":"G Rindi","year":"2010","unstructured":"Rindi G. The ENETS guidelines: the new TNM classification system. Tumori 2010;96:806\u20139.","journal-title":"Tumori"},{"key":"3041_CR23","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2967\/jnumed.113.125336","volume":"55","author":"S Ezziddin","year":"2014","unstructured":"Ezziddin S, Attassi M, Yong-Hing CJ, Ahmadzadehfar H, Willinek W, Gr\u00fcnwald F, et al. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate. J Nucl Med 2014;55:183\u201390.","journal-title":"J Nucl Med"},{"key":"3041_CR24","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00259-003-1142-0","volume":"30","author":"WA Breeman","year":"2003","unstructured":"Breeman WA, De Jong M, Visser TJ, Erion JL, Krenning EP. Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities. Eur J Nucl Med Mol Imaging 2003;30:917\u201320.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3041_CR25","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s00259-002-1054-4","volume":"30","author":"WA Breeman","year":"2003","unstructured":"Breeman WA, van der Wansem K, Bernard BF, van Gameren A, Erion JL, Visser TJ, et al. The addition of DTPA to [177Lu-DOTA0, Tyr3]octreotate prior to administration reduces rat skeleton uptake of radioactivity. Eur J Nucl Med Mol Imaging 2003;30:312\u20135.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3041_CR26","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00259-002-1050-8","volume":"30","author":"DJ Kwekkeboom","year":"2003","unstructured":"Kwekkeboom DJ, Bakker WH, Kam BL, Teunissen JJ, Kooij PP, de Herder WW, et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0), Tyr3]octreotate. Eur J Nucl Med Mol Imaging 2003;30:417\u201322.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3041_CR27","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1200\/JCO.2005.08.066","volume":"23","author":"DJ Kwekkeboom","year":"2005","unstructured":"Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, et al. Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005;23:2754\u201362.","journal-title":"J Clin Oncol"},{"key":"3041_CR28","first-page":"1243","volume":"26","author":"CD Russell","year":"1985","unstructured":"Russell CD, Bischoff PG, Kontzen FN, Rowell KL, Yester MV, Lloyd LK, et al. Measurement of glomerular filtration rate: single injection plasma clearance method without urine collection. J Nucl Med 1985;26:1243\u20137.","journal-title":"J Nucl Med"},{"key":"3041_CR29","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00944177","volume":"10","author":"S Green","year":"1992","unstructured":"Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992;10:239\u201353.","journal-title":"Invest New Drugs"},{"key":"3041_CR30","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1111\/j.1572-0241.2000.03210.x","volume":"95","author":"M Ducreux","year":"2000","unstructured":"Ducreux M, Ruszniewski P, Chayvialle JA, Blumberg J, Cloarec D, Michel H, et al. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol 2000;95:3276\u201381.","journal-title":"Am J Gastroenterol"},{"key":"3041_CR31","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3109\/02841868709113712","volume":"26","author":"K Oberg","year":"1987","unstructured":"Oberg K, Norheim I, Lundqvist G, Wide L. Cytotoxic treatment in patients with malignant carcinoid tumors. Response to streptozocin\u2014alone or in combination with 5-FU. Acta Oncol 1987;26:429\u201332.","journal-title":"Acta Oncol"},{"key":"3041_CR32","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/0959-8049(92)90060-F","volume":"28A","author":"EM Tiensuu Janson","year":"1992","unstructured":"Tiensuu Janson EM, Ahlstr\u00f6m H, Andersson T, Oberg KE. Octreotide and interferon alfa: a new combination for the treatment of malignant carcinoid tumours. Eur J Cancer 1992;28A:1647\u201350.","journal-title":"Eur J Cancer"},{"key":"3041_CR33","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00280-012-2055-z","volume":"71","author":"RL Fine","year":"2013","unstructured":"Fine RL, Gulati AP, Krantz BA, Moss RA, Schreibman S, Tsushima DA, et al. Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience. Cancer Chemother Pharmacol 2013;71:663\u201370.","journal-title":"Cancer Chemother Pharmacol"},{"key":"3041_CR34","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1158\/1078-0432.CCR-06-2053","volume":"13","author":"S Ekeblad","year":"2007","unstructured":"Ekeblad S, Sundin A, Janson ET, Welin S, Granberg D, Kindmark H, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 2007;13:2986\u201391.","journal-title":"Clin Cancer Res"},{"key":"3041_CR35","doi-asserted-by":"crossref","first-page":"R75","DOI":"10.1677\/ERC-09-0108","volume":"17","author":"B Basu","year":"2010","unstructured":"Basu B, Sirohi B, Corrie P. Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin. Endocr Relat Cancer 2010;17:R75\u201390.","journal-title":"Endocr Relat Cancer"},{"key":"3041_CR36","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","volume":"378","author":"ME Pavel","year":"2011","unstructured":"Pavel ME, Hainsworth JD, Baudin E, Peeters M, H\u00f6rsch D, Winkler RE, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011;378:2005\u201312.","journal-title":"Lancet"},{"key":"3041_CR37","doi-asserted-by":"crossref","first-page":"6111","DOI":"10.1158\/1078-0432.CCR-04-0422","volume":"10","author":"MH Shah","year":"2004","unstructured":"Shah MH, Young D, Kindler HL, Webb I, Kleiber B, Wright J, et al. Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors. Clin Cancer Res 2004;10:6111\u20138.","journal-title":"Clin Cancer Res"},{"key":"3041_CR38","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1159\/000324096","volume":"93","author":"AK Pfeifer","year":"2011","unstructured":"Pfeifer AK, Gregersen T, Gr\u00f8nb\u00e6k H, Hansen CP, M\u00fcller-Brand J, Herskind Bruun K, et al. Peptide receptor radionuclide therapy with Y-DOTATOC and (177)Lu-DOTATOC in advanced neuroendocrine tumors: results from a Danish cohort treated in Switzerland. Neuroendocrinology 2011;93:189\u201396.","journal-title":"Neuroendocrinology"},{"key":"3041_CR39","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3413\/Nukmed-0614-13-08","volume":"53","author":"A Sabet","year":"2014","unstructured":"Sabet A, Khalaf F, Yong-Hing CJ, Haslerud T, Ahmadzadehfar H, Guhlke S, et al. Can peptide receptor radionuclide therapy be safely applied in florid bone metastases? A pilot analysis of late stage osseous involvement. Nuklearmedizin 2014;53:54\u20139.","journal-title":"Nuklearmedizin"},{"key":"3041_CR40","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00259-013-2601-x","volume":"41","author":"A Sabet","year":"2014","unstructured":"Sabet A, Ezziddin K, Pape UF, Reichman K, Haslerud T, Ahmadzadehfar H, et al. Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with (177)Lu-octreotate. Eur J Nucl Med Mol Imaging 2014;41:505\u201310.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3041_CR41","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.2967\/jnumed.112.119347","volume":"54","author":"A Sabet","year":"2013","unstructured":"Sabet A, Ezziddin K, Pape UF, Ahmadzadehfar H, Mayer K, P\u00f6ppel T, et al. Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate. J Nucl Med 2013;54:1857\u201361.","journal-title":"J Nucl Med"},{"key":"3041_CR42","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ecl.2010.12.001","volume":"40","author":"B Lawrence","year":"2011","unstructured":"Lawrence B, Gustafsson BI, Kidd M, Pavel M, Svejda B, Modlin IM. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 2011;40:111\u201334.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"3041_CR43","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1245\/s10434-010-1006-3","volume":"17","author":"IM Modlin","year":"2010","unstructured":"Modlin IM, Gustafsson BI, Moss SF, Pavel M, Tsolakis AV, Kidd M. Chromogranin A\u2013biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol 2010;17:2427\u201343.","journal-title":"Ann Surg Oncol"},{"key":"3041_CR44","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s00259-014-2906-4","volume":"42","author":"R Kashyap","year":"2015","unstructured":"Kashyap R, Hofman MS, Michael M, Kong G, Akhurst T, Eu P, et al. Favourable outcomes of (177)Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2015;42:176\u201385.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3041_CR45","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00259-010-1610-2","volume":"38","author":"S Ezziddin","year":"2011","unstructured":"Ezziddin S, Opitz M, Attassi M, Biermann K, Sabet A, Guhlke S, et al. Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging 2011;38:459\u201366.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3041_CR46","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1677\/ERC-08-0017","volume":"15","author":"UF Pape","year":"2008","unstructured":"Pape UF, Berndt U, M\u00fcller-Nordhorn J, B\u00f6hmig M, Roll S, Koch M, et al. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 2008;15:1083\u201397.","journal-title":"Endocr Relat Cancer"},{"key":"3041_CR47","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/cncr.23549","volume":"113","author":"UF Pape","year":"2008","unstructured":"Pape UF, Jann H, M\u00fcller-Nordhorn J, Bockelbrink A, Berndt U, Willich SN, et al. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 2008;113:256\u201365.","journal-title":"Cancer"},{"key":"3041_CR48","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1677\/erc.1.01017","volume":"12","author":"F Panzuto","year":"2005","unstructured":"Panzuto F, Nasoni S, Falconi M, Corleto VD, Capurso G, Cassetta S, et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 2005;12:1083\u201392.","journal-title":"Endocr Relat Cancer"},{"key":"3041_CR49","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1089\/cbr.2009.0641","volume":"24","author":"ML Sierra","year":"2009","unstructured":"Sierra ML, Agazzi A, Bodei L, Pacifici M, Aric\u00f2 D, De Cicco C, et al. Lymphocytic toxicity in patients after peptide-receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE and 90Y-DOTATOC. Cancer Biother Radiopharm 2009;24:659\u201365.","journal-title":"Cancer Biother Radiopharm"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-015-3041-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-015-3041-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-015-3041-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T11:09:05Z","timestamp":1566472145000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-015-3041-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,26]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["3041"],"URL":"https:\/\/doi.org\/10.1007\/s00259-015-3041-6","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,26]]}}}